Abstract 2390: Düsseldorfer-ABCD Trial (Autologous Bone Marrow Cells in Dilated Cardiomyopathy)

Circulation ◽  
2008 ◽  
Vol 118 (suppl_18) ◽  
Author(s):  
Christiana M Schannwell ◽  
Muhammad Yousef ◽  
Carmen M Basalyk ◽  
Tobias Zeus ◽  
Michael Brehm ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Clinical Trials ◽  
Side Effects ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
Left Ventricular ◽  
Control Group ◽  
Group I ◽  
Autologous Bone ◽  
Marrow Cells

Heart failure is a dangerous disease with an increasing frequency. Although conventional drug therapy may delay remodeling, there is no basic therapeutic regime available for preventing or even reversing this process. Several preclinical as well as clinical trials have shown that transplantation of autologous bone marrow cells improved cardiac function after myocardial infarction and chronic heart disease (CAD). We investigated the effects of intracoronary (ic) autologous stem cell transplantation (STX) at patients with non-ischemic dilated cardiomyopathy (DCM). Methods: A total of 10 patients with DCM were included in this study (group I). The control group also consists of 10 age and sex-matched patients with comparable ejection fraction (group II). CAD and myocarditis were excluded. All patients of group I received an ic autologous STX with mononuclear cells. Cell transplantation was performed via the ic administration route. All cells were infused directly into the dominant coronary vessel. To achieve a maximal ischemic stimulus all patients received Dobutamine intravenously and Dipipyridamol by ic application. All 20 patients were re-investigated after 3 months. Results: Three months after ic STX, the global left ventricular ejection fraction increased in patients from 18 ± 1 up to 26 ± 3% (p < 0.01). In parallel the physical ability (functional capacity) rose from 25 to 75 watt (p < 0.01). In addition, we found an improvement of maximum oxygen uptake under stress from 1236 ± 217 up to 1473 ± 198 ml/min (p < 0.01). Furthermore we documented a reduction of arrythmia. An unchanged or even impaired left ventricular function was not observed in any patient of group I. In the control group (group II) no significant changes were documented. No side effects of ic autologous STX were found, particularly no arrythmias, no heart insufficiency, no dyspnoea and no palpitations. Conclusion: These results show that transplantation of autologous bone marrow cells, as well as the ic approach, represents a novel and effective therapeutic procedure for the therapy of DCM. For this method of therapy, no ethical problems exist, and no side effects were observed. However, further experimental studies and controlled prospective clinical trials have to follow.

scholarly journals Refractory Angina Cell Therapy (ReACT) Involving Autologous Bone Marrow Cells in Patients without Left Ventricular Dysfunction: A Possible Role for Monocytes

2009 ◽  
Vol 18 (12) ◽  
pp. 1299-1310 ◽  
Author(s):  
Nelson Americo Hossne ◽  
Adriana Luckow Invitti ◽  
Enio Buffolo ◽  
Silvia Azevedo ◽  
Jose Salvador Rodrigues de Oliveira ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Cell Therapy ◽  
Left Ventricular Dysfunction ◽  
Ventricular Dysfunction ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
Left Ventricular ◽  
Refractory Angina ◽  
Autologous Bone ◽  
Marrow Cells

scholarly journals Clinical and functional evaluation of intramyocardial implantation of autologous bone marrow cells treated with erythropoietinduring the CAD surgery (6-month results)

2019 ◽  
Vol 20 (4) ◽  
pp. 89-99
Author(s):  
A. V. Fomichev ◽  
A. M. Chernyavskiy ◽  
K. K. Gulyaeva ◽  
O. V. Poveschenko ◽  
A. P. Lykov ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Perfusion Defect ◽  
Bone Marrow Cells ◽  
Coronary Bypass ◽  
Autologous Bone Marrow ◽  
Control Group ◽  
Bypass Grafting ◽  
Coronary Bypass Grafting ◽  
Autologous Bone ◽  
Marrow Cells

Aim.Clinical and functional evaluation of the implantation of autologous bone marrow cells treated with erythropoietin in laser channels during coronary bypass grafting in patients with end-stage coronary lesion.Materials and methods.60 patients with coronary artery disease with diffuse and (or) distal right coronary artery disease were randomized into two groups: patients of group 1 (n = 30) underwent coronary bypass grafting, implantation of autologous bone marrow cells treated with erythropoietin in laser channels, patients of the 2nd group (n = 30) were operated with coronary bypass grafting of the left coronary artery system. Assessment of the clinical status, myocardial perfusion and contractility was performed initially, 6 months after the operation.Results.Six months after the operation, there was a more pronounced decrease in angina pectoris (CCS) in the main group compared to the control group, also we revealed a 6-minute walk test scores improvement. Based on two-stage scintigraphy (Tc99) in the main group before the surgical treatment, a rest perfusion defect was 8.5% [3.5, 18.5], a stress-induced perfusion defect – 7.0% [6.0, 12, 3]. In the control group, the rest defect was 9.1% [5.6, 12.4], the stress-induced perfusion defect was 7.3% [6.1, 8.7]. 6 months after surgery rest perfusion defect at the indirect revascularization group was 6.0% [2.5, 16.5] (p = 0.008), a stress-induced defect was 4.0% [1.5, 6.3] (p = 0.05). In the control group, the rest defect was 8.7% [5.3, 10.3], the stress-induced perfusion defect was 6.8% [5.3, 9.1] (p = 0.21). The results of scintigraphy with MIBG showed a left ventricle innervation defect (PID) significant decrease in the main group: initially 15.4% [14.2, 16.3], after 6 months 11.7% [9.3, 13, 2] (p = 0.045). In the control group, there was an unreliable decrease in PID: initially 14.3% [10.2, 17.3], after 6 months 13.8% [9.1, 14.2] (p = 0.14).Conclusion.Our preliminary results revealed more pronounced effect of the new indirect revascularization method expressed as in myocardial perfusion improve, myocardial sympathetic innervation restoration and clinical status improvement in comparison with control group.

scholarly journals The results of intramyocardial implantation of autologous bone marrow cells treated with erythropoietin in the surgical treatment of coronary artery disease with severe lesion of vessels

2019 ◽  
pp. 62-69
Author(s):  
A. V. Fomichev ◽  
A. M. Chernyavsky ◽  
K. K. Gulyaeva ◽  
O. V. Poveshchenko ◽  
A. P. Lykov ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Coronary Artery ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
Control Group ◽  
Autologous Bone ◽  
Artery Disease ◽  
The Right ◽  
Group 1 ◽  
Marrow Cells

Aim. To assess safety and efficacy of intramyocardial implantation of autologous bone marrow cells treated with erythropoietin in surgery for coronary artery disease (CAD).Materials and methods. Eighty patients with CAD with diffuse and (or) distal lesions of the right coronary artery were randomly assigned to two groups: patients of group 1 (n=40) underwent coronary bypass surgery, implantation of autologous bone marrow cells treated with erythropoietin into the lower wall of the left ventricle, patients of group 2 (control group, n=40) underwent bypass surgery of the left coronary artery. Evaluation of the clinical status, perfusion and contractility of the myocardium was performed initially, 6 and 12 months after surgery.Results. Six months after the operation, we found more pronounced decrease of functional class (FC) of angina and improvement in the 6-min walk distance in the main group compared with the control group.Twelve months after surgery, the severity of angina remained at the same level in both groups. In the control group, 45,2% of patients had FC I, 52,3% of patients did not have angina. In both groups, angina return was detected in 1 patient (FC III). According to the results of two-step myocardial scintigraphy with Technetril (Tc99), 6 months after surgery, a significant improvement in myocardial perfusion was observed. In the control group, after 6 months, no significant dynamics of perfusion of the lower wall of the left ventricle was detected.Twelve months after the surgical treatment of the right coronary artery in patients from the group 1 revealed a decrease in the stress defect and the stable perfusion defect. In patients from the control only a significant stress defect was found to decrease.Conclusion. The study demonstrated decrease of FCs, significant improvement in perfusion, functional state of the myocardium and 6-min walk distance in patients of group 1.

Development of cell therapy using autologous bone marrow cells for liver cirrhosis

2005 ◽  
Vol 38 (4) ◽  
pp. 197-202 ◽  
Author(s):  
Isao Sakaida ◽  
Shuji Terai ◽  
Hiroshi Nishina ◽  
Kiwamu Okita
Keyword(s):  
Bone Marrow ◽  
Liver Cirrhosis ◽  
Cell Therapy ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
Autologous Bone ◽  
Marrow Cells

The Safety and Feasibility of the Local Implantation of Autologous Bone Marrow Cells for Ischemic Heart Disease

2003 ◽  
Vol 18 ◽  
pp. S69-S75 ◽  
Author(s):  
Tao-Sheng Li ◽  
Kimikazu Hamano ◽  
Ken Hirata ◽  
Toshiro Kobayashi ◽  
Masahiko Nishida
Keyword(s):  
Bone Marrow ◽  
Heart Disease ◽  
Ischemic Heart Disease ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
Ischemic Heart ◽  
Autologous Bone ◽  
Marrow Cells

scholarly journals Prevention of corticosteroid-induced osteonecrosis in rabbits by intra-bone marrow injection of autologous bone marrow cells

Rheumatology ◽  
2008 ◽  
Vol 47 (5) ◽  
pp. 591-596 ◽  
Author(s):  
T. Asada ◽  
T. Kushida ◽  
M. Umeda ◽  
K. Oe ◽  
H. Matsuya ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow ◽  
Autologous Bone ◽  
Marrow Cells

Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation

Blood ◽  
1987 ◽  
Vol 70 (5) ◽  
pp. 1490-1494 ◽  
Author(s):  
RJ Jones ◽  
M Zuehlsdorf ◽  
SD Rowley ◽  
J Hilton ◽  
GW Santos ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplantation ◽  
Marrow Transplantation ◽  
Bone Marrow Cells ◽  
Autologous Bone Marrow Transplantation ◽  
Tumor Cell Line ◽  
Autologous Bone Marrow ◽  
Incubation Mixture ◽  
Autologous Bone ◽  
Marrow Cells

Abstract We examined the effects of varying incubation conditions on the in vitro activity of 4-hydroperoxycyclophosphamide (4HC). 4HC activity against CFU-GM and against the K562 tumor cell line decreased with increasing the RBC concentration of the incubation mixture. Increasing the concentration of nucleated bone marrow cells in the incubation mixture also decreased the 4HC activity. Evaluation of 53 consecutive patients undergoing autologous bone marrow transplantation (BMT) revealed that the incubation RBC concentration during clinical purging showed a similar effect on CFU-GM recovery. Aldehyde dehydrogenase content of RBCs and nucleated marrow cells appears to be the cause of the inhibition of 4HC activity. Although there was no difference in individual CFU-GM sensitivity to 4HC among normals, previously treated patients undergoing autologous BMT showed significant variability in CFU-GM sensitivity to 4HC. The combined effects of incubation RBC concentration and individual patient 4HC sensitivity appear to account for most of the variability in CFU-GM recovery and speed of hematologic recovery after clinical purging with 4HC.

Sign in / Sign up

Export Citation Format

Share Document